CN101273991A - 四氢吲哚酮/四氢吲唑酮/四氢咔唑衍生物及其盐在制备抗病毒药物中的应用 - Google Patents
四氢吲哚酮/四氢吲唑酮/四氢咔唑衍生物及其盐在制备抗病毒药物中的应用 Download PDFInfo
- Publication number
- CN101273991A CN101273991A CNA2007100648211A CN200710064821A CN101273991A CN 101273991 A CN101273991 A CN 101273991A CN A2007100648211 A CNA2007100648211 A CN A2007100648211A CN 200710064821 A CN200710064821 A CN 200710064821A CN 101273991 A CN101273991 A CN 101273991A
- Authority
- CN
- China
- Prior art keywords
- cell
- virus
- medicine
- heterocycle
- replacement
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Granted
Links
- 238000002360 preparation method Methods 0.000 title claims abstract description 16
- 150000003839 salts Chemical class 0.000 title claims abstract description 13
- 230000000840 anti-viral effect Effects 0.000 title abstract description 15
- YJJUTLWYXYQJNJ-UHFFFAOYSA-N 1,3,3a,4-tetrahydroindol-2-one Chemical class C1C=CC=C2NC(=O)CC21 YJJUTLWYXYQJNJ-UHFFFAOYSA-N 0.000 title abstract description 13
- 239000003814 drug Substances 0.000 title description 74
- 241000700605 Viruses Species 0.000 claims abstract description 42
- 239000003443 antiviral agent Substances 0.000 claims abstract description 16
- 241001529453 unidentified herpesvirus Species 0.000 claims abstract description 6
- 241000709687 Coxsackievirus Species 0.000 claims abstract description 5
- 241000700721 Hepatitis B virus Species 0.000 claims abstract description 5
- 150000001875 compounds Chemical class 0.000 claims description 44
- -1 tetrahydro indole ketone Chemical class 0.000 claims description 31
- 125000000623 heterocyclic group Chemical group 0.000 claims description 16
- 125000002924 primary amino group Chemical group [H]N([H])* 0.000 claims description 8
- 125000003917 carbamoyl group Chemical group [H]N([H])C(*)=O 0.000 claims description 6
- 229910052739 hydrogen Inorganic materials 0.000 claims description 6
- 239000001257 hydrogen Substances 0.000 claims description 6
- 125000004435 hydrogen atom Chemical group [H]* 0.000 claims description 6
- 125000002496 methyl group Chemical group [H]C([H])([H])* 0.000 claims description 6
- 229910052736 halogen Inorganic materials 0.000 claims description 4
- 150000002367 halogens Chemical class 0.000 claims description 4
- 125000002023 trifluoromethyl group Chemical group FC(F)(F)* 0.000 claims description 4
- 125000004093 cyano group Chemical group *C#N 0.000 claims description 2
- QPNLUIFEKCYQHR-UHFFFAOYSA-N 1,2,3a,4-tetrahydroindazol-3-one Chemical compound C1=CCC2C(=O)NNC2=C1 QPNLUIFEKCYQHR-UHFFFAOYSA-N 0.000 abstract description 12
- XKLNOVWDVMWTOB-UHFFFAOYSA-N 2,3,4,9-tetrahydro-1h-carbazole Chemical class N1C2=CC=CC=C2C2=C1CCCC2 XKLNOVWDVMWTOB-UHFFFAOYSA-N 0.000 abstract description 5
- 241000709675 Coxsackievirus B3 Species 0.000 abstract description 4
- 210000004027 cell Anatomy 0.000 description 64
- 229940079593 drug Drugs 0.000 description 36
- IAZDPXIOMUYVGZ-UHFFFAOYSA-N Dimethylsulphoxide Chemical compound CS(C)=O IAZDPXIOMUYVGZ-UHFFFAOYSA-N 0.000 description 24
- 238000003556 assay Methods 0.000 description 16
- 239000012895 dilution Substances 0.000 description 16
- 238000010790 dilution Methods 0.000 description 16
- 238000002474 experimental method Methods 0.000 description 16
- 231100000915 pathological change Toxicity 0.000 description 16
- 230000036285 pathological change Effects 0.000 description 16
- 239000007788 liquid Substances 0.000 description 15
- 231100000135 cytotoxicity Toxicity 0.000 description 12
- 230000003013 cytotoxicity Effects 0.000 description 12
- 230000000694 effects Effects 0.000 description 12
- 239000006144 Dulbecco’s modified Eagle's medium Substances 0.000 description 11
- 230000001988 toxicity Effects 0.000 description 11
- 231100000419 toxicity Toxicity 0.000 description 11
- 239000000523 sample Substances 0.000 description 10
- 238000012360 testing method Methods 0.000 description 10
- 230000000120 cytopathologic effect Effects 0.000 description 9
- 230000003612 virological effect Effects 0.000 description 8
- 241001597008 Nomeidae Species 0.000 description 7
- 230000010261 cell growth Effects 0.000 description 7
- 239000006228 supernatant Substances 0.000 description 7
- UIIMBOGNXHQVGW-UHFFFAOYSA-M Sodium bicarbonate Chemical compound [Na+].OC([O-])=O UIIMBOGNXHQVGW-UHFFFAOYSA-M 0.000 description 6
- 239000013553 cell monolayer Substances 0.000 description 6
- 238000004737 colorimetric analysis Methods 0.000 description 6
- 239000012531 culture fluid Substances 0.000 description 6
- 239000001963 growth medium Substances 0.000 description 6
- 239000002609 medium Substances 0.000 description 6
- 231100000028 nontoxic concentration Toxicity 0.000 description 6
- 238000012856 packing Methods 0.000 description 6
- 230000004083 survival effect Effects 0.000 description 6
- 238000011282 treatment Methods 0.000 description 6
- 230000002155 anti-virotic effect Effects 0.000 description 5
- 210000002249 digestive system Anatomy 0.000 description 5
- 208000002672 hepatitis B Diseases 0.000 description 5
- 230000002401 inhibitory effect Effects 0.000 description 5
- 231100000820 toxicity test Toxicity 0.000 description 5
- 241000700588 Human alphaherpesvirus 1 Species 0.000 description 4
- 241000700584 Simplexvirus Species 0.000 description 4
- 230000009471 action Effects 0.000 description 4
- 239000003153 chemical reaction reagent Substances 0.000 description 4
- 230000001934 delay Effects 0.000 description 4
- 230000003203 everyday effect Effects 0.000 description 4
- 208000015181 infectious disease Diseases 0.000 description 4
- 239000002777 nucleoside Substances 0.000 description 4
- 238000002560 therapeutic procedure Methods 0.000 description 4
- KCXVZYZYPLLWCC-UHFFFAOYSA-N EDTA Chemical compound OC(=O)CN(CC(O)=O)CCN(CC(O)=O)CC(O)=O KCXVZYZYPLLWCC-UHFFFAOYSA-N 0.000 description 3
- 102000004142 Trypsin Human genes 0.000 description 3
- 108090000631 Trypsin Proteins 0.000 description 3
- MKUXAQIIEYXACX-UHFFFAOYSA-N aciclovir Chemical compound N1C(N)=NC(=O)C2=C1N(COCCO)C=N2 MKUXAQIIEYXACX-UHFFFAOYSA-N 0.000 description 3
- 244000309466 calf Species 0.000 description 3
- 238000005138 cryopreservation Methods 0.000 description 3
- 230000009849 deactivation Effects 0.000 description 3
- 230000029087 digestion Effects 0.000 description 3
- 201000010099 disease Diseases 0.000 description 3
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 description 3
- 238000001914 filtration Methods 0.000 description 3
- 230000008676 import Effects 0.000 description 3
- 210000005229 liver cell Anatomy 0.000 description 3
- 238000012423 maintenance Methods 0.000 description 3
- 238000000034 method Methods 0.000 description 3
- 239000010413 mother solution Substances 0.000 description 3
- 210000002966 serum Anatomy 0.000 description 3
- 229910000030 sodium bicarbonate Inorganic materials 0.000 description 3
- 235000017557 sodium bicarbonate Nutrition 0.000 description 3
- 239000000243 solution Substances 0.000 description 3
- 238000004448 titration Methods 0.000 description 3
- 238000012546 transfer Methods 0.000 description 3
- 239000012588 trypsin Substances 0.000 description 3
- 210000003501 vero cell Anatomy 0.000 description 3
- BAXOFTOLAUCFNW-UHFFFAOYSA-N 1H-indazole Chemical compound C1=CC=C2C=NNC2=C1 BAXOFTOLAUCFNW-UHFFFAOYSA-N 0.000 description 2
- FRUWMYWEARDNTC-UHFFFAOYSA-N 2,3,3a,4-tetrahydro-1h-indole Chemical compound C1C=CC=C2NCCC21 FRUWMYWEARDNTC-UHFFFAOYSA-N 0.000 description 2
- 208000030507 AIDS Diseases 0.000 description 2
- 241000282552 Chlorocebus aethiops Species 0.000 description 2
- 208000009889 Herpes Simplex Diseases 0.000 description 2
- 241000701074 Human alphaherpesvirus 2 Species 0.000 description 2
- 102000014150 Interferons Human genes 0.000 description 2
- 108010050904 Interferons Proteins 0.000 description 2
- 239000012980 RPMI-1640 medium Substances 0.000 description 2
- IWUCXVSUMQZMFG-AFCXAGJDSA-N Ribavirin Chemical compound N1=C(C(=O)N)N=CN1[C@H]1[C@H](O)[C@H](O)[C@@H](CO)O1 IWUCXVSUMQZMFG-AFCXAGJDSA-N 0.000 description 2
- 208000036142 Viral infection Diseases 0.000 description 2
- 230000003602 anti-herpes Effects 0.000 description 2
- 239000000427 antigen Substances 0.000 description 2
- 102000036639 antigens Human genes 0.000 description 2
- 108091007433 antigens Proteins 0.000 description 2
- 239000012228 culture supernatant Substances 0.000 description 2
- 231100000433 cytotoxic Toxicity 0.000 description 2
- 230000001472 cytotoxic effect Effects 0.000 description 2
- IRSCQMHQWWYFCW-UHFFFAOYSA-N ganciclovir Chemical compound O=C1NC(N)=NC2=C1N=CN2COC(CO)CO IRSCQMHQWWYFCW-UHFFFAOYSA-N 0.000 description 2
- 208000006454 hepatitis Diseases 0.000 description 2
- 229940079322 interferon Drugs 0.000 description 2
- 210000003292 kidney cell Anatomy 0.000 description 2
- 231100001134 median toxic concentration Toxicity 0.000 description 2
- 238000011160 research Methods 0.000 description 2
- 239000012488 sample solution Substances 0.000 description 2
- 230000001629 suppression Effects 0.000 description 2
- 239000000725 suspension Substances 0.000 description 2
- 230000009385 viral infection Effects 0.000 description 2
- 229940100050 virazole Drugs 0.000 description 2
- 238000005303 weighing Methods 0.000 description 2
- 208000019775 Back disease Diseases 0.000 description 1
- 206010008342 Cervix carcinoma Diseases 0.000 description 1
- UHDGCWIWMRVCDJ-CCXZUQQUSA-N Cytarabine Chemical compound O=C1N=C(N)C=CN1[C@H]1[C@@H](O)[C@H](O)[C@@H](CO)O1 UHDGCWIWMRVCDJ-CCXZUQQUSA-N 0.000 description 1
- 241000701022 Cytomegalovirus Species 0.000 description 1
- 206010059866 Drug resistance Diseases 0.000 description 1
- 238000002965 ELISA Methods 0.000 description 1
- 241000196324 Embryophyta Species 0.000 description 1
- 208000007514 Herpes zoster Diseases 0.000 description 1
- 102100034343 Integrase Human genes 0.000 description 1
- 235000010624 Medicago sativa Nutrition 0.000 description 1
- 240000004658 Medicago sativa Species 0.000 description 1
- 108091034117 Oligonucleotide Proteins 0.000 description 1
- 108010019160 Pancreatin Proteins 0.000 description 1
- 102000011195 Profilin Human genes 0.000 description 1
- 108050001408 Profilin Proteins 0.000 description 1
- CZPWVGJYEJSRLH-UHFFFAOYSA-N Pyrimidine Chemical compound C1=CN=CN=C1 CZPWVGJYEJSRLH-UHFFFAOYSA-N 0.000 description 1
- 108010092799 RNA-directed DNA polymerase Proteins 0.000 description 1
- 231100000645 Reed–Muench method Toxicity 0.000 description 1
- 201000003176 Severe Acute Respiratory Syndrome Diseases 0.000 description 1
- 208000006105 Uterine Cervical Neoplasms Diseases 0.000 description 1
- 208000018756 Variant Creutzfeldt-Jakob disease Diseases 0.000 description 1
- 238000010521 absorption reaction Methods 0.000 description 1
- 229960004150 aciclovir Drugs 0.000 description 1
- 238000011951 anti-virus test Methods 0.000 description 1
- 239000000074 antisense oligonucleotide Substances 0.000 description 1
- 238000012230 antisense oligonucleotides Methods 0.000 description 1
- 206010064097 avian influenza Diseases 0.000 description 1
- 230000000903 blocking effect Effects 0.000 description 1
- 208000005881 bovine spongiform encephalopathy Diseases 0.000 description 1
- 239000006285 cell suspension Substances 0.000 description 1
- 230000001413 cellular effect Effects 0.000 description 1
- 230000007541 cellular toxicity Effects 0.000 description 1
- 201000010881 cervical cancer Diseases 0.000 description 1
- 238000006243 chemical reaction Methods 0.000 description 1
- 239000003795 chemical substances by application Substances 0.000 description 1
- 238000002512 chemotherapy Methods 0.000 description 1
- 231100000263 cytotoxicity test Toxicity 0.000 description 1
- 230000002950 deficient Effects 0.000 description 1
- 238000013461 design Methods 0.000 description 1
- 238000011161 development Methods 0.000 description 1
- 230000000857 drug effect Effects 0.000 description 1
- 229960004396 famciclovir Drugs 0.000 description 1
- GGXKWVWZWMLJEH-UHFFFAOYSA-N famcyclovir Chemical compound N1=C(N)N=C2N(CCC(COC(=O)C)COC(C)=O)C=NC2=C1 GGXKWVWZWMLJEH-UHFFFAOYSA-N 0.000 description 1
- GSTNAAOCEHQZDY-UHFFFAOYSA-N formic acid phosphane Chemical compound [PH4+].[O-]C=O GSTNAAOCEHQZDY-UHFFFAOYSA-N 0.000 description 1
- 229960002963 ganciclovir Drugs 0.000 description 1
- 231100000283 hepatitis Toxicity 0.000 description 1
- 230000036737 immune function Effects 0.000 description 1
- 239000003112 inhibitor Substances 0.000 description 1
- JTEGQNOMFQHVDC-NKWVEPMBSA-N lamivudine Chemical compound O=C1N=C(N)C=CN1[C@H]1O[C@@H](CO)SC1 JTEGQNOMFQHVDC-NKWVEPMBSA-N 0.000 description 1
- 229960001627 lamivudine Drugs 0.000 description 1
- 150000002611 lead compounds Chemical class 0.000 description 1
- 230000031700 light absorption Effects 0.000 description 1
- 238000005259 measurement Methods 0.000 description 1
- 244000005700 microbiome Species 0.000 description 1
- 230000000116 mitigating effect Effects 0.000 description 1
- 238000012986 modification Methods 0.000 description 1
- 230000004048 modification Effects 0.000 description 1
- 230000035772 mutation Effects 0.000 description 1
- 239000013642 negative control Substances 0.000 description 1
- 150000003833 nucleoside derivatives Chemical class 0.000 description 1
- 230000003287 optical effect Effects 0.000 description 1
- 150000004989 p-phenylenediamines Chemical class 0.000 description 1
- 229940055695 pancreatin Drugs 0.000 description 1
- 239000013641 positive control Substances 0.000 description 1
- 230000002265 prevention Effects 0.000 description 1
- 238000011321 prophylaxis Methods 0.000 description 1
- 150000007660 quinolones Chemical class 0.000 description 1
- 238000012216 screening Methods 0.000 description 1
- 239000002356 single layer Substances 0.000 description 1
- 241000894007 species Species 0.000 description 1
- 238000001228 spectrum Methods 0.000 description 1
- 208000024891 symptom Diseases 0.000 description 1
- 208000011580 syndromic disease Diseases 0.000 description 1
- 230000001225 therapeutic effect Effects 0.000 description 1
- 238000001890 transfection Methods 0.000 description 1
- 230000009466 transformation Effects 0.000 description 1
- 230000014616 translation Effects 0.000 description 1
- 210000002845 virion Anatomy 0.000 description 1
Landscapes
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
Abstract
Description
Claims (6)
Priority Applications (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
CN200710064821A CN101273991B (zh) | 2007-03-28 | 2007-03-28 | 四氢吲哚酮/四氢吲唑酮/四氢咔唑衍生物及其盐在制备抗病毒药物中的应用 |
Applications Claiming Priority (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
CN200710064821A CN101273991B (zh) | 2007-03-28 | 2007-03-28 | 四氢吲哚酮/四氢吲唑酮/四氢咔唑衍生物及其盐在制备抗病毒药物中的应用 |
Publications (2)
Publication Number | Publication Date |
---|---|
CN101273991A true CN101273991A (zh) | 2008-10-01 |
CN101273991B CN101273991B (zh) | 2010-05-26 |
Family
ID=39994126
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
CN200710064821A Active CN101273991B (zh) | 2007-03-28 | 2007-03-28 | 四氢吲哚酮/四氢吲唑酮/四氢咔唑衍生物及其盐在制备抗病毒药物中的应用 |
Country Status (1)
Country | Link |
---|---|
CN (1) | CN101273991B (zh) |
Cited By (10)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CN101955461A (zh) * | 2010-10-08 | 2011-01-26 | 广州暨南生物医药研究开发基地有限公司 | 一种Hsp90抑制剂Xbj-B11及其制备方法与应用 |
CN101481353B (zh) * | 2008-01-08 | 2011-07-20 | 广东同德药业有限公司 | 四氢吲唑酮或四氢吲哚酮取代的吲唑衍生物及其盐 |
CN104592203A (zh) * | 2015-01-30 | 2015-05-06 | 广州暨南生物医药研究开发基地有限公司 | 一种2-氨基-4-四氢吲唑取代的苯甲酰胺化合物及其在制备抗肿瘤药物中的应用 |
CN104817544A (zh) * | 2015-03-23 | 2015-08-05 | 三峡大学 | 一种四氢吲哚-4-酮肟类药物,制备方法及其应用 |
CN105311636A (zh) * | 2015-11-18 | 2016-02-10 | 暨南大学 | 一种抗疱疹病毒软膏剂及其制备方法 |
WO2016040809A1 (en) * | 2014-09-11 | 2016-03-17 | Esanex, Inc. | Indazolyl- and indolyl-benzamide derivatives |
CN105693819A (zh) * | 2016-03-10 | 2016-06-22 | 三峡大学 | 一种四氢吲哚-4酮三肽类化合物,制备方法及其在抗肿瘤药物中的用途 |
CN115400121A (zh) * | 2022-04-29 | 2022-11-29 | 佛山病原微生物研究院 | 一种snx-2112在制备用于抗腺病毒感染的药物中的用途 |
CN116444438A (zh) * | 2023-04-17 | 2023-07-18 | 深圳市人民医院 | 一种苯甲酰胺类化合物及其制备方法、使用方法和应用 |
CN116554105A (zh) * | 2023-04-26 | 2023-08-08 | 深圳市人民医院 | 新型多效苯甲酰胺类化合物及制备方法、使用方法和应用 |
Family Cites Families (4)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
WO2000018734A1 (de) * | 1998-09-25 | 2000-04-06 | Boehringer Ingelheim Pharma Kg | Neue substituierte indolinone mit inhibierender wirkung auf verschiedene kinasen und cyclin/cdk-komplexe |
US20090170906A1 (en) * | 2004-11-22 | 2009-07-02 | Kristjan Gudmundsson | Hcv inhibitors |
KR20070114763A (ko) * | 2005-02-25 | 2007-12-04 | 세레넥스, 인코포레이티드 | 테트라히드로인돌론 및 테트라히드로인다졸론 유도체 |
CN100575341C (zh) * | 2005-06-14 | 2009-12-30 | 北京国药龙立生物医药新技术有限公司 | 四氢吲哚酮的衍生物和四氢吲唑酮的衍生物及它们的应用 |
-
2007
- 2007-03-28 CN CN200710064821A patent/CN101273991B/zh active Active
Cited By (17)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CN101481353B (zh) * | 2008-01-08 | 2011-07-20 | 广东同德药业有限公司 | 四氢吲唑酮或四氢吲哚酮取代的吲唑衍生物及其盐 |
CN101955461A (zh) * | 2010-10-08 | 2011-01-26 | 广州暨南生物医药研究开发基地有限公司 | 一种Hsp90抑制剂Xbj-B11及其制备方法与应用 |
CN101955461B (zh) * | 2010-10-08 | 2012-11-21 | 广州暨南生物医药研究开发基地有限公司 | 一种Hsp90抑制剂Xbj-B11及其制备方法与应用 |
US10246421B2 (en) | 2014-09-11 | 2019-04-02 | Esanex, Inc. | Indazolyl- and indolyl-benzamide derivatives |
WO2016040809A1 (en) * | 2014-09-11 | 2016-03-17 | Esanex, Inc. | Indazolyl- and indolyl-benzamide derivatives |
CN104592203A (zh) * | 2015-01-30 | 2015-05-06 | 广州暨南生物医药研究开发基地有限公司 | 一种2-氨基-4-四氢吲唑取代的苯甲酰胺化合物及其在制备抗肿瘤药物中的应用 |
CN104817544A (zh) * | 2015-03-23 | 2015-08-05 | 三峡大学 | 一种四氢吲哚-4-酮肟类药物,制备方法及其应用 |
CN105311636B (zh) * | 2015-11-18 | 2017-12-12 | 暨南大学 | 一种抗疱疹病毒软膏剂及其制备方法 |
CN105311636A (zh) * | 2015-11-18 | 2016-02-10 | 暨南大学 | 一种抗疱疹病毒软膏剂及其制备方法 |
CN105693819A (zh) * | 2016-03-10 | 2016-06-22 | 三峡大学 | 一种四氢吲哚-4酮三肽类化合物,制备方法及其在抗肿瘤药物中的用途 |
CN105693819B (zh) * | 2016-03-10 | 2019-06-18 | 三峡大学 | 一种四氢吲哚-4酮三肽类化合物,制备方法及其在抗肿瘤药物中的用途 |
CN115400121A (zh) * | 2022-04-29 | 2022-11-29 | 佛山病原微生物研究院 | 一种snx-2112在制备用于抗腺病毒感染的药物中的用途 |
CN115400121B (zh) * | 2022-04-29 | 2023-05-23 | 佛山病原微生物研究院 | 一种snx-2112在制备用于抗腺病毒感染的药物中的用途 |
CN116444438A (zh) * | 2023-04-17 | 2023-07-18 | 深圳市人民医院 | 一种苯甲酰胺类化合物及其制备方法、使用方法和应用 |
CN116444438B (zh) * | 2023-04-17 | 2024-02-13 | 深圳市人民医院 | 一种苯甲酰胺类化合物及其制备方法、使用方法和应用 |
CN116554105A (zh) * | 2023-04-26 | 2023-08-08 | 深圳市人民医院 | 新型多效苯甲酰胺类化合物及制备方法、使用方法和应用 |
CN116554105B (zh) * | 2023-04-26 | 2024-02-20 | 深圳市人民医院 | 苯甲酰胺类化合物及制备方法、使用方法和应用 |
Also Published As
Publication number | Publication date |
---|---|
CN101273991B (zh) | 2010-05-26 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
CN101273991A (zh) | 四氢吲哚酮/四氢吲唑酮/四氢咔唑衍生物及其盐在制备抗病毒药物中的应用 | |
CA2662677C (en) | Kinase inhibitors for preventing or treating pathogen infection and method of use thereof | |
CN104244945B (zh) | 用于治疗hcv的方法 | |
Clercq | Highlights in antiviral drug research: antivirals at the horizon | |
CN106167488A (zh) | 治疗癌症及非肿瘤病症的方法 | |
CN102666537A (zh) | 治疗黄病毒科病毒感染的氮杂吲唑 | |
CN106715431A (zh) | Toll样受体调节剂的固体形式 | |
CN107022008A (zh) | 广谱地抑制人类冠状病毒感染的多肽及其应用 | |
CN105705511A (zh) | 用于治疗hcv的氘化核苷前药 | |
CN103380132B (zh) | 菲啶大环丙型肝炎丝氨酸蛋白酶抑制剂 | |
CN103561739A (zh) | 可用于治疗hcv感染的经取代的脂肪芬、环芬、异芬、杂芬、杂-异芬以及金属茂 | |
CN105793288A (zh) | 抗pdl1抗体配制剂 | |
CN106456615A (zh) | 抗病毒化合物、医药组合物及其使用方法 | |
CN104479018A (zh) | 抗-pd-l1抗体及它们用于增强t细胞功能的用途 | |
JP2002509140A (ja) | トリアジン抗ウイルス化合物 | |
WO2005072826A2 (en) | Compositions and use of tyrosine kinase inhibitors to treat pathogenic infection | |
CN102448458A (zh) | 治疗黄病毒科病毒感染的方法和组合物 | |
CN105886476A (zh) | 用于增强病毒效力的组合物和方法 | |
CN103269593A (zh) | 烷基亚磺酰基取代的噻唑化物化合物 | |
CN109467566A (zh) | 用于治疗和/或预防与肝炎病毒相关的疾病或病症的双二氮杂双环化合物 | |
CN103316344A (zh) | 延缓或逆转在治疗肺癌中耐药的egfr-tki复合物及其制剂 | |
CN107952078A (zh) | 一种载药体系的合成方法及其新用途 | |
CN107603946A (zh) | 黄芪多糖在防护辐射A549细胞产生旁效应对BMSCs损伤中的应用 | |
CN102295609B (zh) | 2-[(取代苯氨基)羰基甲硫基]-6-环己甲基-3h-嘧啶-4-酮类化合物、其合成方法及用途 | |
CN107184572A (zh) | 一种ape1抑制剂及其在制备用于治疗肿瘤和血管异常增生性疾病药物中的应用 |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
C06 | Publication | ||
PB01 | Publication | ||
C10 | Entry into substantive examination | ||
SE01 | Entry into force of request for substantive examination | ||
ASS | Succession or assignment of patent right |
Owner name: GUANGDONG TONGDE PHARMACEUTICAL CO., LTD. Free format text: FORMER OWNER: BEIJING TRADITIONAL CHINESE MEDICINE LONGLI BIOLOGICAL MEDICINE NEW TECHNOLOGY CO., LTD. Effective date: 20100308 |
|
C41 | Transfer of patent application or patent right or utility model | ||
COR | Change of bibliographic data |
Free format text: CORRECT: ADDRESS; FROM: 100036 ROOM 2105, BUILDING 19, NO.4, CUIWEI ROAD, HAIDIAN DISTRICT, BEIJING CITY TO: 524018 NO.4, WEST 5TH ROAD, ZHENCHUAN AVENUE, ZHANJIANG CITY, GUANGDONG PROVINCE |
|
TA01 | Transfer of patent application right |
Effective date of registration: 20100308 Address after: 524018 Guangdong city of Zhanjiang province Shen Chuan Road West five road No. 4 Applicant after: GUANGDONG TONGDE PHARMACEUTICAL Co.,Ltd. Applicant after: Guangzhou Jinan Biomedical Research and Development center Address before: 100036 Beijing city Haidian District Cuiwei Road No. 4 Building 19 room 2105 Applicant before: Beijing Gylongly Biomedtech Ltd. Applicant before: Guangzhou Jinan Biomedical Research and Development center |
|
C14 | Grant of patent or utility model | ||
GR01 | Patent grant | ||
TR01 | Transfer of patent right | ||
TR01 | Transfer of patent right |
Effective date of registration: 20180209 Address after: 510662 -29, No. 339 (A workshop), No. -29 (A) on the suburb of Conghua District, Guangzhou City, China Co-patentee after: Guangzhou Jinan Biomedical Research and Development center Patentee after: GUANGZHOU SALIAI STEMCELL SCIENCE AND TECHNOLOGY Co.,Ltd. Address before: 524018 Guangdong city of Zhanjiang province Shen Chuan Road West five road No. 4 Co-patentee before: Guangzhou Jinan Biomedical Research and Development center Patentee before: GUANGDONG TONGDE PHARMACEUTICAL Co.,Ltd. |
|
CP03 | Change of name, title or address | ||
CP03 | Change of name, title or address |
Address after: 510320 unit 403a, 4th floor, production area, No. 1, helix 4th Road, International Biological Island, Huangpu District, Guangzhou, Guangdong Province Patentee after: Guangzhou kangqilai precision medical technology Co.,Ltd. Patentee after: Guangzhou Jinan Biomedical Research and Development center Address before: 510662 1st floor, no.339-29, Hengjiang Road, Chengjiao street, Conghua District, Guangzhou City, Guangdong Province Patentee before: GUANGZHOU SALIAI STEMCELL SCIENCE AND TECHNOLOGY Co.,Ltd. Patentee before: Guangzhou Jinan Biomedical Research and Development center |
|
TR01 | Transfer of patent right | ||
TR01 | Transfer of patent right |
Effective date of registration: 20220713 Address after: 510610 room 4105, No. 365, Tianhe North Road, Tianhe District, Guangzhou, Guangdong Province (office only) Patentee after: Guangzhou Shaobo Holding Group Co.,Ltd. Patentee after: Guangzhou Jinan Biomedical Research and Development center Address before: 510320 unit 403a, 4th floor, production area, No. 1, helix 4th Road, International Biological Island, Huangpu District, Guangzhou, Guangdong Province Patentee before: Guangzhou kangqilai precision medical technology Co.,Ltd. Patentee before: Guangzhou Jinan Biomedical Research and Development center |